according to the origins of the lenticular perforators or by simply splitting it in half. 10 However, this method only addresses the M1 segment, and the precise location of thrombus in the other segments remains unclear. Introduction of an objective, easy-to-assess, and precise method of describing the location of thrombus in the MCA is therefore important.
In this study, we measured the length of the MCA from the carotid T to the beginning of the thrombus (distance to thrombus [DT]) to avoid the above-mentioned problems and to obtain a continuous numeric parameter for comparison with outcomes in patients with acute MCA occlusion treated with IVT.
Methods
This study was approved by our local institutional review board.
Patient Selection
Patients treated for ischemic stroke by our institution between January 1, 2009, and April 30, 2014, were retrospectively screened for eligibility. The inclusion criteria, according to criteria as published by Toni and colleagues, 13 for the present study were as follows:
CT angiography (CTA)-proven vessel occlusion in the MCA territory. Completed treatment with a full dose of IVT according to a previously published protocol. 13 Complete documentation of the clinical course, including the initial National Institutes of Health Stroke Scale (NIHSS) score, NIHSS score at 7 days, and modified Rankin Scale (mRS) score at 90 days (90d-mRS). No additional vasculopathy in either a different intracranial territory or the cervical vessels (especially no relevant preceding stenosis).
Image Analysis
All CTA examinations were performed using a 64-section multidetector scanner (Brilliance 64, Philips, Best, The Netherlands) with a slice thickness of 1 mm. CTA images were reformatted in the coronal plane, and a 10-mm maximum intensity projection image was rendered using the free software Osirix (Pixmeo SARL, Switzerland). The exact location of the occlusion was determined, and DT was measured as the distance from the center of the carotid T to the beginning of the thrombus. The center of the carotid T was defined as the crossing point of the virtual elongation of the MCA, the internal carotid artery, and the proximal anterior cerebral artery. The DT was measured as a curved line along the center of the MCA (Figure 1 ). DT analysis was performed by a single rater (B.F.) with >5 years in stroke CTA interpretation. The rater was completely blinded to all patient characteristics while performing the measurements. The thrombus length was measured on the CTA images, in accordance with the gold standard described in the study by Riedel and colleagues, 9, 14 and was categorized as <5, 5 to 8, or >8 mm based on their results.
Statistical Analysis
Statistical analyses were performed using SPSS software version 20 (IBM, Armonk, NY). Data were tested for normality using the Shapiro-Wilk test. Correlations between clinical information and the DT or thrombus length were calculated using a correlation analysis with Spearman ρ. The probability of a good clinical outcome (defined as 90d-mRS ≤2) was calculated using logistic regression analysis. Differences between partially arbitrarily chosen groups of DT (<5 mm/5-10 mm/10-16 mm/16-30 mm/>30 mm; the 16 mm value as a result of the logistic regression analysis) were analyzed with univariate analysis using ANOVA on ranks with a Tukey post hoc analysis followed by multivariate analysis. Noncontinuous variables like mRS and NIHSS are presented as median (interquartile range). All other data are shown as mean±SD unless indicated otherwise. Statistical significance was set at P<0.05.
Results
Of 621 patients screened, 136 met the inclusion criteria for this study. The demographic characteristics of the patients are shown in the Table and Table I in the online-only Data Supplement.
We were able to identify the exact location of the occlusion and measure DT in all patients. The mean DT was 19±13.7 mm (range, 1-77 mm). Figure 1 shows a representative proximal occlusion and more distal occlusion ( Figure 1A and 1B).
The probability of a good clinical outcome according to DT was evaluated using logistic regression analysis. There was an exponential relationship between DT and 90d-mRS. Logistic regression analysis showed that probability of good outcome was increasing with DT and became >50% at DT>16 mm ( Figure 2 ; P<0.001).
There was a significant, however weak, negative correlation using Spearman ρ between DT and 90d-mRS (R= −0.21; P=0.014). There were also differences in outcome among different categories of DT: for DT <5 mm, only 20% of patients had a good clinical outcome; and for DT >30 mm, 57% had a good clinical outcome (P=0.041). Statistical significance in good clinical outcome between DT<5 mm and DT=5 to 10 mm/DT=10 to 16 mm/DT=16 to 30 mm was shortly missed (P=0.054/0.061/0.087). The 90-day mortality rate was 55.6% in patients with DT<5 mm and 4.8% in patients with DT>30 mm (P=0.007; Figure 3A and 3B). There was no significant correlation using Spearman ρ between DT and the short-term change in neurological status (R=0.037; P=0.696), defined as the difference between the initial NIHSS score and the NIHSS score on day 7 after IVT (eg, DT<5 mm: NIHSS score improvement 4 [−2 to 8]; DT>30 mm: NIHSS score improvement 3 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] ).
In a multivariate analysis, DT turned out to be an independent predictor of good clinical outcome with on odds ratio of 1.68 (95% confidence interval, 1.49-1.72), independent Table II in the online-only Data Supplement). None of the obtained parameters were distributed normally. We analyzed the clinical outcome according to the thrombus length. There was no significant correlation between the thrombus length and 90d-mRS (R=0.153; P=0.32), and there were no significant differences in clinical outcome among different categories of thrombus length (P=0.698). There was a highly significant negative correlation between DT and thrombus length: a longer thrombus occurred significantly more often with a short DT than with a long DT (R=0.529; P<0.001; Figure 4A and 4B).
Discussion
We found that DT was a highly significant predictor of clinical outcome in patients with acute MCA occlusion treated with IVT.
There are few recent studies that compared the location of MCA occlusion on angiography (CTA or digital subtraction angiography) with clinical outcomes in patients with ischemic stroke. The likelihood of an unfavorable outcome was reported to increase with a more proximal occlusion in patients treated with IVT or mechanical thrombectomy. 8, 10 These studies used analyses based on the occluded MCA segment and restricted their comparisons to M1 segment occlusion with or without M2 segment occlusion. In their CT-based study, Rohan and colleagues 8 found that the length of M1 occlusion was significantly correlated with the clinical outcome. They measured the stump length, which is comparable with the DT we measured, but excluded it as a parameter from the outcome correlation analysis. Furthermore, they used a complicated analytic method based on evaluation of 4D-CTA images on dedicated workstations, which makes clinical application of their method in the acute setting difficult. In another angiography-based study, Behme and colleagues 10 analyzed patients treated by mechanical thrombectomy after M1 occlusion. They split the location of the M1 occlusion into 2 groups: a proximal group with occlusion of the lenticulostriate perforators visible on digital subtraction angiography, and a distal group without occlusion of the lenticulostriate perforators. They found that patients with proximal M1 occlusion had unfavorable outcomes compared with patients with distal M1 occlusion. These findings indicate the importance of determining the exact location of the vascular occlusion in MCA stroke when evaluating the prognosis or making therapeutic decisions. However, use of this system is restricted to assessment of the proximal segments of the MCA, and the complicated analytic method makes it difficult to compare findings among studies and difficult to use the system in acute settings. Measurement of the DT as in the present study seems to be more precise and more useful.
In their 2011 study, Riedel and colleagues 9 found that a thrombus length of ≥8 mm measured by their previously described noncontrast CT method was associated with a low rate of recanalization after IVT (<1%). They also found that patients with a long thrombus were unlikely to have a good clinical outcome. In our study, we found no correlation between thrombus length and the clinical outcome measured by 90d-mRS. However, a longer thrombus was significantly more frequent with a shorter DT. These data could be interpreted as if the location of the thrombus therefore seems to have a greater impact on the clinical outcome than thrombus length. It is possible that the effects on outcome attributed to recanalization in the study by Riedel and colleagues 9 were because of the location of the thrombus, which they did not include in their analyses.
The benefit of treatment of stroke with IVT has been shown in several large multicenter trials. 2 In many of these trials, the Logistic regression analysis showed an exponential relationship between DT and the probability of a good clinical outcome after treatment with intravenous thrombolysis using recombinant tissue plasminogen activator. For DT >16 mm, a good clinical outcome was more likely than a poor outcome (P<0.001). DT indicates distance from the carotid T to the thrombus.
by guest on April 13, 2017 http://stroke.ahajournals.org/ Downloaded from type of occlusion was not included in the analyses and was not considered in the inclusion criteria. However, our data in combination with other published data suggest that the outcome after IVT varies according to the location of the occlusion. A recently published subgroup analysis of several large stroke studies found that patients with a single distal MCA occlusion (the equivalent of a long DT) had a high likelihood of a good clinical outcome independent of successful recanalization, which is the objective of IVT. 15 As patients with a short DT have a poor outcome after MCA stroke treated with IVT, and the clinical outcome after distal MCA occlusion may be independent of the initial treatment success, it may be necessary to reconsider which patients actually benefit from IVT. Considering our results in combination with previously published results, it is possible that only patients with a specific type of occlusion benefit from IVT, for example, as those with a DT between 16 and 30 mm and a thrombus length of <5 mm. 9, 15 In a subgroup analysis of our data, these patients had the highest rate (>80%) of a good clinical outcome. However, because of the small sample size of this subgroup, this tendency did not reach significance and must be interpreted with caution.
This study is limited by its single-center, retrospective design and the relatively small number of patients. Because of the retrospective design, no data of vessel recanalization was available to evaluate this aspect in the light of our results. Another limitation is that only one, although experienced, rater measured the DT values and therefore we were not able to assess inter-rater reliability. Furthermore, the thrombus length as measured in this study has to be compared with caution 
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with the studies of Riedel et al. 2010 14 and 2011 9 because the measurement could not be performed in exactly the same way because of the retrospective design and the imaging data available.
In conclusion, we found that DT was a highly significant predictor of clinical outcome in patients with acute MCA occlusion treated with IVT. Based on our results in combination with previously published results, IVT might not be the ideal treatment for all patients with acute MCA stroke and other therapy forms, for example mechanical thrombectomy, might be warranted. Advanced and easily obtainable imaging analysis that includes measurement of the DT and thrombus length may provide information that can improve patient triage and may enable specifically tailored therapy, thereby improving overall patient outcomes. The results could also play an important role for future multicenter trials as they enable to evaluate the benefit of IVT versus other treatment options exactly in those patients that have a low probability of a good clinical outcome with IVT. 
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